Where Does the Future Lie for Systemic Delivery of Drugs by Inhalation?

One of the highlights this morning at DDP 2009 was the panel moderated by Martin E. Judge, PhD, Sourcing Director of Diabetes Research Unit at Novo Nordisk A/S which featuring Alfred E. Mann, Chairman and Chief Executive Officer of Mannkind Corporation, Igor Gonda the President & Chief Executive Officer of Aradigm Corporation and John Patton the Chief Research Fellow of Nektar titled "Where Does the Future Lie for Systemic Delivery of Drugs by Inhalation? ".

The panelists discussed the value and benefit of inhalable insulin. John Patton discussed where he felt Exubera. had stumbled while Al Mann discussed the uniqueness of Mannkind's inhalable insulin currently in trials. In addition, they discussed how pricing is affecting reimbursement and risk and offered thoughts on how companies need to communicate and measure the benefit ratio.

Dr. Judge asked the panelists if inhalable insulin can and will demonstrate improved efficacy and safety. They all agreed that this was the big challenge. While that was one of the causes of the Exubera failure, Al Mann contends his product will meet this challenge.

Share this article with your social network, just click below to share now!

Share |